Every 10-Q that Establishment Labs Holdings Inc. (ESTA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ESTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESTA filings page.
Establishment Labs Holdings Inc., a medical device company focused on Motiva silicone breast implants, reported strong top-line growth while remaining unprofitable for the period ended June 30, 2026. Revenue reached $67.5 million in the quarter and $127.4 million for the first half of 2026, up 31.7% and 37.5%, respectively, versus 2025. Growth was driven mainly by the U.S. launch, with U.S. sales rising sharply and a more favorable geographic and product mix lifting gross margin to 70.6% in Q2 and 70.7% year-to-date.
Operating loss narrowed to $4.3 million in Q2 and $10.8 million for the first half, while net loss improved to $11.7 million in Q2 and $25.1 million year-to-date, or $0.39 and $0.84 per share. Operating cash outflow improved but remained negative at $20.9 million for the first half. Cash stood at $71.2 million and accumulated deficit at $520.9 million, with shareholders’ equity of $21.6 million. The company refinanced and upsized its Oaktree term loan into a new facility of up to $300 million, with $265 million funded and no principal due until 2031, increasing outstanding debt to $271.6 million. Management states it is in compliance with debt covenants and believes existing cash and cash generation can cover at least the next 12 months, while it continues to pursue patent litigation in multiple jurisdictions with outcomes not yet determinable.
Establishment Labs Holdings Inc. reported first-quarter 2026 results showing strong growth but continued losses. Revenue rose to $59.9 million, up from $41.4 million a year earlier, driven by broader sales of Motiva Implants, including the United States.
Gross profit increased to $42.3 million, while the operating loss narrowed to $6.5 million and net loss improved to $13.4 million, or $0.45 per share. Cash and cash equivalents were $68.1 million, with net cash used in operating activities reduced to $4.3 million from $20.7 million. The balance sheet shows total assets of $351.0 million and shareholders’ equity of $14.8 million, alongside $246.4 million of Oaktree term debt and related obligations.
Establishment Labs (ESTA) reported Q3 2025 results. Revenue reached $53.8 million, up from $40.2 million a year ago, with gross profit of $37.7 million. Operating loss narrowed to $4.0 million and net loss was $11.1 million, or $0.38 per share.
North America contributed $11.9 million in Q3 revenue versus $0.3 million in the prior year period. For the first nine months, revenue was $146.5 million and net loss was $48.4 million.
Cash and cash equivalents were $70.6 million at quarter-end. Year-to-date net cash used in operating activities was $50.7 million. Note payable, net, increased to $246.5 million from $219.6 million at year-end 2024, and shareholders’ equity declined to $16.4 million from $53.1 million. The company had 29,057,868 common shares outstanding as of November 6, 2025.